Drugs / NuvaRing

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) NUVARING 2001-10-03 fda.gov

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05360576 Feb → Jul 2022 Lupin Research Inc Completed No outcome recorded
Phase 43 trials
Phase 4 NCT02445989 May 2016 → Nov 2018 HIV infectious disease, bacterial vaginosis University of Washington Completed No outcome recorded
Phase 4 NCT02432404 Mar 2016 → Nov 2021 bacterial vaginosis University of Washington Completed No outcome recorded
Phase 4 NCT02367833 Jan 2015 → Dec 2017 bone disorder Penn State University Completed No outcome recorded
Phase not applicable5 trials
NCT01266759 Jul 2008 → Sep 2010 menstrual disorder Mansoura University Completed No outcome recorded
NCT00565240 Nov 2007 → Sep 2009 University of Saskatchewan Completed No outcome recorded
NCT00369967 Feb 2007 → Jul 2009 Virginia Commonwealth University Terminated No outcome recorded
NCT00374387 Sep 2006 → Aug 2009 University Hospital, Ghent Completed No outcome recorded
NCT01298128 Feb 2006 → Mar 2010 infertility disorder University of Toronto Terminated No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT00710606 Comparator Jun → Dec 2008 Columbia University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Nuvaring ClinicalTrials.gov intervention name — accepted as the source's own label NCT00374387
8

NCT00369967

NCT02432404

NCT05360576

NCT00565240

NCT02445989

NCT01298128

NCT01266759

NCT00710606

Known as Contraceptive Vaginal Ring ClinicalTrials.gov intervention name — accepted as the source's own label NCT02367833
Modality Other / unclassified “It is a combined hormonal contraceptive containing etonogestrel (a progesterone) and ethinyl estradiol (an estrogen)” NCT00369967
Route Other “One of the biggest obstacles to use of the contraceptive vaginal ring in clinical practice is having the patient overcome the idea of vaginally inserting the ring” NCT00369967